- Stocks
- Healthcare
- NASDAQ: CTMX

Price (delayed)

$1.63

Market cap

$107.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.49

Enterprise value

-$6.63M

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics,

CTMX's debt is down by 19% year-on-year and by 6% since the previous quarter

CTMX's revenue is up by 9% year-on-year and by 2.7% since the previous quarter

CTMX's equity has dropped by 63% year-on-year and by 29% since the previous quarter

CytomX Therapeutics's net income has shrunk by 51% YoY and by 5% QoQ

What are the main financial stats of CTMX

Market
Valuations
Earnings

Shares outstanding

65.95M

Market cap

$107.5M

Enterprise value

-$6.63M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.19

Price to sales (P/S)

1.47

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

-0.09

Revenue

$72.62M

EBIT

-$96.88M

EBITDA

-$91.05M

Free cash flow

-$138.1M

Per share
Balance sheet
Liquidity

EPS

-$1.49

Free cash flow per share

-$2.11

Book value per share

$0.74

Revenue per share

$1.11

TBVPS

$3.94

Total assets

$260.09M

Total liabilities

$211.38M

Debt

$16.08M

Equity

$48.71M

Working capital

$133.33M

Debt to equity

0.33

Current ratio

2.34

Quick ratio

2.31

Net debt/EBITDA

1.25

Margins
Efficiency
Dividend

EBITDA margin

-125.4%

Gross margin

100%

Net margin

-133.4%

Operating margin

-134.5%

Return on assets

-30.6%

Return on equity

-121.9%

Return on invested capital

-211.3%

Return on capital employed

-60.3%

Return on sales

-133.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the CytomX Therapeutics stock price performed over time

Intraday

-2.4%

1 week

2.52%

1 month

8.67%

1 year

-66.67%

YTD

-62.36%

QTD

-10.93%

How have CytomX Therapeutics's revenue and profit performed over time

Revenue

$72.62M

Gross profit

$72.62M

Operating income

-$97.66M

Net income

-$96.88M

Gross margin

100%

Net margin

-133.4%

The operating income has dropped by 51% year-on-year and by 6% since the previous quarter

CytomX Therapeutics's net income has shrunk by 51% YoY and by 5% QoQ

The company's operating margin fell by 39% YoY and by 3.3% QoQ

CTMX's net margin is down by 38% year-on-year and by 2.6% since the previous quarter

What is CytomX Therapeutics's growth rate over time

What is CytomX Therapeutics stock price valuation

P/E

N/A

P/B

2.19

P/S

1.47

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

-0.09

The EPS has contracted by 25% YoY and by 4.9% from the previous quarter

The stock's price to book (P/B) is 69% less than its 5-year quarterly average of 7.1 and 22% less than its last 4 quarters average of 2.8

CTMX's equity has dropped by 63% year-on-year and by 29% since the previous quarter

The stock's P/S is 79% less than its 5-year quarterly average of 7.0 and 55% less than its last 4 quarters average of 3.3

CTMX's revenue is up by 9% year-on-year and by 2.7% since the previous quarter

How efficient is CytomX Therapeutics business performance

The ROIC has shrunk by 142% YoY and by 20% QoQ

CTMX's return on assets has dropped by 87% year-on-year and by 17% since the previous quarter

CTMX's ROE has dropped by 78% year-on-year and by 33% since the previous quarter

The ROS has contracted by 38% YoY and by 2.6% from the previous quarter

What is CTMX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CTMX.

How did CytomX Therapeutics financials performed over time

CTMX's total assets is 23% more than its total liabilities

CTMX's total assets is down by 35% YoY and by 12% from the previous quarter

The company's total liabilities fell by 22% YoY and by 8% QoQ

CTMX's debt is 67% smaller than its equity

The debt to equity has soared by 120% year-on-year and by 32% since the previous quarter

CTMX's equity has dropped by 63% year-on-year and by 29% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.